Minimed Group, INC. (MMED) — SEC Filings
Latest SEC filings for Minimed Group, INC.. Recent S-1 filing on Dec 19, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.
View Minimed Group, INC. on SEC EDGAR
Overview
Minimed Group, INC. (MMED) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 19, 2025: MiniMed Group, Inc. (MMED) is preparing for an initial public offering, spinning off from Medtronic plc. The company, founded in 1983, specializes in automated insulin delivery (AID) systems, including integrated continuous glucose monitors (CGMs), insulin delivery devices (pumps and smart pens), an
Sentiment Summary
Across 1 filings, the sentiment breakdown is: 1 mixed. The dominant filing sentiment for Minimed Group, INC. is mixed.
Filing Type Overview
Minimed Group, INC. (MMED) has filed 1 S-1 with the SEC between Dec 2025.
Recent Filings (1)
-
MiniMed IPO: Diabetes Tech Spinoff Targets $18B Market, Double-Digit Growth
— S-1 · Dec 19, 2025 Risk: medium
MiniMed Group, Inc. (MMED) is preparing for an initial public offering, spinning off from Medtronic plc. The company, founded in 1983, specializes in automated
Risk Profile
Risk Assessment: Of MMED's 1 recent filings, 0 were flagged as high-risk, 1 as medium-risk, and 0 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Alfred E. Mann
- Courtney Nelson Wills
Industry Context
The diabetes technology market is a rapidly growing segment within the broader healthcare industry, driven by increasing diabetes prevalence and advancements in digital health. MiniMed operates in the highly competitive Automated Insulin Delivery (AID) space, which requires significant R&D investment and regulatory expertise. Key trends include the integration of CGMs and insulin delivery devices, the development of sophisticated algorithms for automated dosing, and a focus on improving patient outcomes and quality of life.
Top Tags
Diabetes Technology (1) · IPO (1) · Medical Devices (1) · Automated Insulin Delivery (1) · Medtronic Spinoff (1) · Healthcare Innovation (1) · Continuous Glucose Monitoring (1)
Key Numbers
- Annual Revenue: $2.7B — Generated by the Diabetes Operating Unit in FY25, showing recent double-digit growth.
- Estimated Market Size: $18B — Current market for MiniMed's diabetes technologies, expected to grow double-digits annually.
- Founding Year: 1983 — Year MiniMed was founded by Alfred E. Mann.
- Years of Legacy: 40 — MiniMed's trusted legacy in diabetes care.
- Countries Served: 80+ — Number of countries where MiniMed has improved lives.
- People Worldwide: 37M+ — Number of people requiring intensive insulin therapy globally.
- Daily Decisions: 180 — Additional decisions a person with diabetes makes daily.
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Minimed Group, INC. (MMED)?
Minimed Group, INC. has 1 recent SEC filings from Dec 2025, including 1 S-1. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MMED filings?
Across 1 filings, the sentiment breakdown is: 1 mixed. The dominant sentiment is mixed.
Where can I find Minimed Group, INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Minimed Group, INC. (MMED) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Minimed Group, INC.?
Financial highlights for Minimed Group, INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for MMED?
The investment thesis for MMED includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Minimed Group, INC.?
Key executives identified across Minimed Group, INC.'s filings include Alfred E. Mann, Courtney Nelson Wills.
What are the main risk factors for Minimed Group, INC. stock?
Of MMED's 1 assessed filings, 0 were flagged high-risk, 1 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Minimed Group, INC.?
Forward guidance and predictions for Minimed Group, INC. are extracted from SEC filings as they are enriched.